Smith & Nephew SNATS (NYSE:SNN) versus Evolus (NASDAQ:EOLS) Head to Head Analysis

Smith & Nephew SNATS (NYSE:SNN) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Valuation & Earnings

This table compares Smith & Nephew SNATS and Evolus”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16 billion	2.14	$625.00 million	N/A	N/A
Evolus	$301.79 million	1.44	-$51.64 million	($0.67)	-9.85

Smith & Nephew SNATS has higher revenue and earnings than Evolus.

Insider and Institutional Ownership

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Smith & Nephew SNATS and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Evolus	-14.39%	N/A	-19.03%

Risk and Volatility

Smith & Nephew SNATS has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Smith & Nephew SNATS and Evolus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0	5	1	0	2.17
Evolus	1	1	4	0	2.50

Smith & Nephew SNATS currently has a consensus price target of $30.93, indicating a potential upside of 0.12%. Evolus has a consensus price target of $16.00, indicating a potential upside of 142.42%. Given Evolus’ stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Smith & Nephew SNATS.

Summary

Evolus beats Smith & Nephew SNATS on 6 of the 11 factors compared between the two stocks.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.